The pooled sensitivity of MIBG scintigraphy to detect PD was 89% (95% Cl: 86-91%); the pooled specificity of MIBG scintigraphy to discriminate between PD and MSA was 77% (95% Cl: 68-84%). The area under the ROC curve was 0.93.\n\nConclusions: MIBG scintigraphy is an accurate test for PD detection and differential THZ1 Cell Cycle inhibitor diagnosis between PD and MSA; this method shows high sensitivity and adequate specificity in this field. Nevertheless, possible causes of false negative and false positive findings should be considered when interpreting the
scintigraphic results. (C) 2011 Elsevier B.V. All rights reserved.”
“Background A new 8% ciclopirox-medicated nail lacquer (P-3051), based on a new technology, revealed superior properties in terms of affinity to keratin, nail permeation, and ease of use. Objective This study aims to assess the efficacy and safety of P-3051 vs. the market see more 8% ciclopirox nail lacquer.\n\nMethods This is a multicentre, randomized, three-arm, placebo-controlled, parallel groups, evaluator-blinded study. Overall, 467 patients
with onychomycosis of at least one big toenail were randomized to receive P-3051, the reference drug or placebo in a 2 : 2 : 1 ratio for a 48-week treatment by daily application, followed by a 12-week follow-up.\n\nResults The study satisfied its objective by demonstrating that P-3051 was both superior to placebo and non-inferior to reference in the complete cure rate after a 48-week active treatment period. Switching the non-inferiority Stattic supplier to superiority hypothesis, the superiority of P-3051 vs. reference was nearly significant at week 48 (confirmed at week 52), and it was significant at week 60 (cure rate for P-3051 is 119% higher than reference; P < 0.05). Altogether, the results on primary endpoint exceed expectations; superiority test was performed also on secondary endpoints to confirm the superiority trend of the study. At the end of follow-up, percentages of patients who achieved the endpoint ‘responder’
in the P-3051 group were 66% higher than reference (P < 0.05), and those who achieved the endpoint ‘decrease of diseased nail’ were 40% higher (P < 0.05).\n\nConclusion Ciclopirox 8% hydrolacquer is more active than reference ciclopirox nail lacquer in the treatment of onychomycosis.”
“Background: Epidemiological and clinical studies suggest comorbidity between prostate cancer (PCA) and cardiovascular disease (CVD) risk factors. However, the relationship between these two phenotypes is still not well understood. Here we sought to identify shared genetic loci between PCA and CVD risk factors. Methods: We applied a genetic epidemiology method based on conjunction false discovery rate (FDR) that combines summary statistics from different genome-wide association studies (GWAS), and allows identification of genetic overlap between two phenotypes.
No related posts.